|
- Lundbeck | Cafepharma
Lundbeck is making a big push on the company’s capital reallocation initiative, handing over its operations in 27 markets to partners Lundbeck will transition to a partnership model in 27 markets through collaborations with the Swixx Group, Zuellig Pharma and NewBridge Pharmaceuticals, the Danish pharma said Tuesday
- Pharma Biotech Companies | Cafepharma Message Boards | Pharma Sales . . .
Anonymous discussion boards for pharmaceutical and biotech companies
- Avadel Pharma | Cafepharma
Lundbeck has said it won't raise its offer to buy Avadel Pharma any further, clearing the way for the sleep disorder specialist to complete a merger with Alkermes
- CGRPs | Cafepharma
The FDA has OK’d eptinezumab, the prize in Lundbeck’s $2 billion acquisition of Alder Like rival offerings from Amgen Novartis, Eli Lilly and Teva, the antibody blocks the calcitonin gene-related peptide, which is believed to dilate blood vessels in the brain and cause pain
- November 19 2025 - After Lundbecks surprise bid, Alkermes sweetens . . .
After Lundbeck's surprise bid, Alkermes sweetens deal to acquire AvadelLundbeck board, Alkermes boardPfizer in $41 5 million settlement with Texas over ADHD drug for childrenPfizer boardMerck HIV therapy matches Gilead’s Biktarvy in late-stage trial
- Avadel Pharmaceuticals | Cafepharma
Facing the fact that Lundbeck’s unexpected offer for Avadel Pharmaceuticals was sweeter, Alkermes has come back to the negotiating table with a higher bid it believes can seal the deal Alkermes and Avadel have reached an accord on a new offer that would see Alkermes pay up to $22 50 per Avadel share to acquire the company, according to a Nov 19 press release The upgraded bid features $21
- Alkermes | Cafepharma
Facing the fact that Lundbeck’s unexpected offer for Avadel Pharmaceuticals was sweeter, Alkermes has come back to the negotiating table with a higher bid it believes can seal the deal Alkermes and Avadel have reached an accord on a new offer that would see Alkermes pay up to $22 50 per Avadel share to acquire the company, according to a Nov 19 press release The upgraded bid features $21
- Lundbeck planning for four novel drugs in phase 3 in 2026 | Cafepharma
Denmark's Lundbeck has said that efforts to build its R D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from its recently announced $2 6 billion takeover of Longboard Pharma
|
|
|